A B S T R A C T Kinetic data analysis was used to derive a six-compartment computer model which describes the in vivo [3H]25-hydroxyvitamin D3 ([3H]25-OHD3) metabolism in control and strontium rachitic chicks. Plasma concentrations of 25-OHD3 (13 pmol/ml) and 24, 25-dihydroxyvitamin D3 (0.9 pmol/ml) were 18 and 125% greater than controls, respectively, whereas the corresponding level for la,25-dihydroxyvitamin D3 (0.3 pmol/ml) was only 30% of control. Plasma disappearance of 25-OHD3 was fitted using a two-compartment model in which the metabolite extrapolated half-life was nearly twice as large for strontium rachitic chicks (71 compared to 41 h). Intestinal sequestration of la,25-dihydroxyvitamin D3 was assumed to be irreversible and was fitted by a single exponential term in which metabolite uptake rate and tissue concentration in strontium rickets was suppressed to 20 and 10% of control, respectively. In contrast, uptake of 25-OHD3 by the intestine was observed to occur by a reversible process in which metabolite concentration was 45% greater in the strontium rachitic compared to control group. The developed compartment model accepts time-dependent control or perturbed metabolite data for the plasma and (or) intestinal pools and provides quantitative values for metabolite pool size, flux rate, and turnover time.
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INTRODUCTION
The function of vitamin D to enhance intestinal calcium absorption, bone mineral mobilization, and calcification is well appreciated (1, 2) . However, to effect such actions vitamin D must be metabolically activated, initially in the liver (25-hydroxylation) (3, 4) and subsequently in the kidney (la-hydroxylation) (5, 6) , resulting in the synthesis of la,25-dihydroxyReceived for publication I July 1976 and in revised form 17 June 1977. vitamin DI (la,25-(OH)2D)2 (7, 8) . This compound contains the greatest biological activity of any known vitamin D metabolite (9) (10) (11) . Control of renal la,25-(OH)2D synthesis, and consequently the physiological response of vitamin D-dependent processes, is influenced to a large extent by the action of parathyroid hormone (PTH) on the kidney la-hydroxylase system (12) (13) (14) . A lesion in this control system can result in the development of disease-states which affect calcium homeostasis (15-17) (e.g., renal-and vitamin D-dependent rickets). Insights into the prevention and treatment of such metabolic diseases are dependent upon understanding how perturbations in kidney la-hydroxylase activity affect la,25-(OH)2DI synthesis and turnover at the whole organism level.
Experiments on this subject have succeeded in providing voluminous qualitative data on the in vivo metabolism of 25-hydroxyvitamin D3 (25-OHD3), yet a void exists regarding the kinetics of in vivo 25-OHD3 metabolism and how the synthetic and degradative parameters are changed in disease-perturbed states. Since PTH and calcium (18, 19) are both purported to be involved in modulating 25-OHD3 metabolism, we elected to study the kinetics of in vivo 25-OHD3 metabolism in a strontium rachitic animal model in which there is a lesion in the PTH component of the calcium homeostatic control system. Recent studies in rats have shown that strontium's inhibition of kidney la-hydroxylase and stimulation of 24-hydroxylase activities (20, 21) [9] ) and tap water ad libitum for 16 days at which time the animals were used for experimentation.
Dietary regimen. The diets used during the experimental periods were similar to the previously mentioned semipurified diet except they contained purified casein, were supplemented with arginine, and differed in methionine and glycine content (casein 25.6%, arginine 1.2%, methionine 0.4%, and glycine 1.0%). Two purified diets that differed in their calcium and strontium content were used. They consisted of: (a) control diet (Ca = 0.13 mmol/g feed, no Sr), (b) strontium diet (Ca = 0.013 mmol/g feed, Sr = 0.13 mmol/g feed). At the beginning of the experimental period chicks were divided into two groups and given either control or strontium feed (pair-group fed, 15 g/chick per day), deionized water, and oral vitamin D3 supplements (650 pmol bi-daily). This regimen was continued for 11 days at which time the chicks were used for the in vivo study of x 106 dpm, 2.4 x 104 dpm/pmol), with a 6-8-ml blood sample obtained by cardiac puncture at a specified time post injection. Chicks were subsequently killed by cervical dislocation and the intestine (duodenum to cecum) removed, flushed with cold 0.9% NaCl, and immediately frozen. A chloroform lipid-extract was prepared from each plasma and intestinal mucosa sample by using a mixture of chloroformmethanol (22) . The [26,27- and subsequent sequestration of the trihydroxy metabolite by intestinal tissue was evaluated by using a solvent system which resolves la,24-25-(OH)2D3 (chloroform:hexane; 80:20; 170 ml) for chromatography of intestinal mucosal tissue. Plasma metabolic data for each animal was expressed as total plasma dpm with 131I-albumin used to estimate the plasma volume as 6.7% of the body weight. All radioactivity measurements were made with a Packard Liquid Scintillation Spectrophotometer model 3375 (Packard Instrument Co., Inc., Downers Grove. Ill.)
Plasma calcium ana strontium. Blood was taken in heparinized syringes via cardiac puncture and plasma prepared by centrifugation (1,500g, 10 min). Plasma samples were diluted with 0.5% LaCl3 (1:40) and total plasma calcium and strontium were determined by atomic absorption spectrophotometry (9) used in a competitive binding assay for plasma 25-OHD3 as described by Belsey et al. (24) . Plasma assay samples were extracted with chloroform-methanol (22) . The 25-OHD3 was isolated from the lipid extract through use of minisilicic acid column chromatography (25) before its quantitation by use of the binding assay. Bone ash determination. Tibiae were cleaned of muscle and marrow material then extracted with ethanol-and diethylether (24 h each) before ashing for 24 h at 600°C. Percent ash was determined from the bone ash weight to dry bone weight ratio.
Kinetic analysis. The data were analyzed and fitted to multicompartmental models using the National Institute of Health Simulation Analysis and Modeling (SAAM) program described by Berman et al., and an IBM-360 digital computer (IBM Corp., White Plains, N. Y.) (26) (27) (28) . The program derives values for the parameters of an assumed model to yield a least-squares fit of the data. This is accomplished by the generation of theoretical data based on initial estimates of the kinetic parameters for the model, and the calculation of partial derivatives for each theoretical datum with respect to each adjustable parameter in the model. Equations of conditions and normal equations are generated from the partial derivatives, and corrections for the initial estimates of the parameter values are calculated. This procedure is iterated until a least-squares fit of data is obtained, which yields a set of values for the parameters along with estimates of their uncertainties. RESULTS
The dietary strontium treatment was designed to effect a minimal perturbation in animal weight and plasma calcium concentration, prompting alterations in the kidney 25-OHD3 metabolism and bone mineralization. Strontium-treated chicks showed a high plasma strontium concentration and significantly lower bone ash (P < 0.01), indicative of rachitic bone lesions, but they did not differ statistically from the control group with regards to body weight or plasma calcium concentration (Table I) . Plasma 25-OHD3 concentration within the two groups remained essentially constant throughout the experimental period, with a + 10% variation. The kinetic parameters derived for 25-OHD3 metabolism were therefore analyzed using steadystate theory.
Model nomenclature
The following terms and figures were used in developing the kinetic model for 25-OHD3 metabolism:
Compartment. Represented by a circle and denotes a subdivision of a model used for analysis of experimental observations.
Compartment size (V). The total amount ofmaterial (pmol) in a compartment (i.e., pool).
Rate constant (X). The fraction of total material in a compartment that is transported to another compartment per unit time. Results are expressed in reciprocal hours (h-1). Where number subscripts are used, the first denotes the plasma metabolite comparment into which a metabolite enters and the second, the plasma metabolite compartment from which the metabolite leaves (e.g., X3,, indicates the fraction of metabolite which leaves compartment one, via metabolic alteration, and enters compartment three). Irreversible loss from the model system (out) is designated "O" (e.g., X0,1 indicates irreversible loss of metabolite from compartment one due to excretory, metabolic, and(or) target organ sequestration processes).
Transport (R). The total amount of material in a throughout the study (P < 0.01) which suggested a slower metabolite disappearance rate for the experimental group (Fig. la) . Evidence to this effect was obtained by calculating the plasma half-life values for [3H]25-OHD3. Animals in the strontium group had consistantly higher values in comparison to the control group for the rapid (1.8 compared to 1 h) and slow-extrapolated (41 compared to 71 h) disappearance phases (Table I ). The higher half-life values could be attributed to decreases in efflux of metabolite from plasma into both the exchangeable and metabolicirreversible 25-OHD3 pools (Table II) . A small but significant elevation in total plasma 25-OHD3 (Table  III) was also observed in the strontium group, which contributes to the longer [3H]25-OHD3 half-life. (Fig. ld, f) .
Plasma appearance of [3H] la,25-(OH)2D3 was markedly suppressed in the strontium group (Fig. lc) , with transport of the metabolite being 43% of control (Table II) (Fig. le) , which was 25% greater than control values for transport of 25-OHD3 to 24,25-(OH)2D3 (Table II) . Even more illustrative of this phenomenon are the calculations for the 24,25-(OH)2D3 plasma pool size. Strontium-treated animals had a plasma pool of 11 pmol, which was over two times the estimated value for the control pool (5 pmol) (Table III) . This significant difference (P < 0.01) appears attributable to a decrease in the plasma efflux rate for 24,25-(OH)2D3 in the strontium compared to control group (i.e., A = 0.043 h-l for strontium and 0.076 h-l for control).
Intestinal [3H ]1 a,25-(OH)2D3 appearance
Intestinal fH] 1a,25-(OH)2D3 sequestration was significantly decreased (P < 0.01) in strontium compared to calcium-treated chicks (Fig. 2a) . The intestine was treated as a metabolite sink and the data fitted to a single compartment with irreversible metabolite flow. There was a necessity for including a delay scheme (Fig. 2b, compartments (Fig.  2c) . Rapid metabolite appearance and decline suggested an exchange phenomenon with plasma 25- OHD3, similar to that previously discussed for the plasma metabolite and its possible extravascular ex-change. Intestinal [3H]25-OHD3 was therefore treated as a component of the extravascular pool (i.e., compartment two) in which the data could be fitted to a single compartment with the reversible route for metabolite exchange (Fig. 2d) . Similar to intestinal [3H]-la,25-(OH)2D3 appearance, it was necessary to include a delay component (compartment eight) when fitting the strontium [3H]25-OHD3 data. As observed in Fig. 2c there was an initial higher rise in intestinal [3H]25-OHD3 for the strontium group, resulting in a metabolite transport which was greater than four times that observed in control chicks (Table II (31) (32) (33) , although the metabolite's disappearance in the chick occurs much faster (6-to 10-fold increase) than that observed in humans.
The necessity for a 25-OHD3 nonvascular exchange pool in the model for plasma [3H]25-OHD3 disappearance (Fig. lb) suggest a general tissue distribution and exchange for the metabolite which is similar to vitamin D3 (34) . Specific binding of 25-OHD3 has been observed in a variety of tissues for both the rat and chick (35, 36 (Fig. 2d) (38) . The plasma concentration ratio of 25-OHD3 to 1a,25-(OH)2D3 was 10 for control and 43 for strontium animals, which is lower than that reported for humans (range 40-1,000) (13, 23) . Such low precursorproduct ratios in the chick appear due to the high values for 1a,25-(OH)2D3 relative to 25-OHD3, which were augmented by use of a control diet that contains one-halfthe normal amount of calcium (i.e., 0.13 mmol/g compared to 0.26 mmol/g). The relatively high rate of 25-OHD3 metabolism may also be contributory as exemplified kinetically by the control chick's catalyticpotential to replace its la,25-(OH)2D3 plasma pool every 20 h (i.e., plasma pool divided by transport rate, Tables II, III) .
The model tor the intestinal appearance of 1a,25-(OH)2D3 and 25-OHD3 was developed assuming an irreversible process for [3H] la,25-(OH)2D3, and a reversible process for [3H]25-OHD3 due to the lack of definitive information on possible exchange processes. These assumptions were based on data for the metabolites appearance and (or) exchange in mucosal tissue (Fig. 2 ) and in vitro binding constant for la,25-(OH)2D3 with the intestinal cytosol receptor (39) . Intestinal handling of the two metabolites was strikingly different. A rapid influx and subsequent efflux was observed for [3H]25-OHD3, whereas [3H] la,25-(OH)2D3 was continuing to increase in concentration at 24 h after the pulse [3H]-25-OHD3 injection. Such data is characteristic of specific and nonspecific hormone sequestration by a target organ, in which high-and low-cellular binding affinities are observed for biologically active (e.g., la,25-(OH)2D3) and nonactive forms (e.g., 25-OHD3) of the hormone (40) . The presence of an intestinal cytosol receptor which has a greater affinity for la,25-(OH)2D3 than for 25-OHD3 has been described (39) and shown to have a Kd of 2.2 nM; indicating that the binding process is approaching irreversibility. Saturation of such high affinity-binding sites occurs in vitro at 10 nM la,25-(OH)2D3 (39) , which indicates that such intestinal binding sites are nearly saturated with la,25-(OH)2D3 in the present study (intestinal concentration range, 1.6-16 nM; Table IV) . It would appear, therefore, that de novo synthesized metabolite would most effectively compete for binding sites in newly synthesized epithelial cells. Accordingly, we assumed that la,25-(OH)2D3 intestinal binding and turnover was strongly dependent upon the epithelial cell life and therefore constituted prodominantly an irreversible process. Such a high tissue specificity for 1a,25-(OH)2D3 became especially evident when the intestinal concentration of metabolite was 5 to 15 times greater than that of plasma. In contrast, 25- OHD3 was present in intestinal tissue at only _10% of the concentration observed in plasma.
The genesis of suppressed intestinal-calcium absorption in strontium rickets became evident when 25 
